C4 Therapeutics (CCCC) Competitors $1.52 +0.01 (+0.66%) Closing price 04:00 PM EasternExtended Trading$1.52 0.00 (0.00%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. RAPP, ERAS, BNTC, ITOS, RVNC, ABVX, FULC, SLDB, CKPT, and TECXShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Rapport Therapeutics (RAPP), Erasca (ERAS), Benitec Biopharma (BNTC), iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), Abivax (ABVX), Fulcrum Therapeutics (FULC), Solid Biosciences (SLDB), Checkpoint Therapeutics (CKPT), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Its Competitors Rapport Therapeutics Erasca Benitec Biopharma iTeos Therapeutics Revance Therapeutics Abivax Fulcrum Therapeutics Solid Biosciences Checkpoint Therapeutics Tectonic Therapeutic Rapport Therapeutics (NASDAQ:RAPP) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Do institutionals & insiders hold more shares of RAPP or CCCC? 78.8% of C4 Therapeutics shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor RAPP or CCCC? In the previous week, Rapport Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 1 mentions for Rapport Therapeutics and 0 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.89 beat Rapport Therapeutics' score of 0.93 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Rapport Therapeutics Positive C4 Therapeutics Very Positive Which has stronger valuation & earnings, RAPP or CCCC? Rapport Therapeutics has higher earnings, but lower revenue than C4 Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$78.31M-$3.45-3.42C4 Therapeutics$35.58M3.03-$105.32M-$1.47-1.03 Do analysts rate RAPP or CCCC? Rapport Therapeutics presently has a consensus price target of $28.00, suggesting a potential upside of 137.29%. C4 Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 689.47%. Given C4 Therapeutics' higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Rapport Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is RAPP or CCCC more profitable? Rapport Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -259.60%. Rapport Therapeutics' return on equity of -25.48% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A -25.48% -24.63% C4 Therapeutics -259.60%-45.86%-28.96% SummaryC4 Therapeutics beats Rapport Therapeutics on 8 of the 14 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.22M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-1.0321.3126.1719.90Price / Sales3.03278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book0.507.518.055.38Net Income-$105.32M-$55.05M$3.15B$248.50M7 Day Performance-1.30%2.45%1.85%2.97%1 Month Performance14.29%7.33%4.81%6.02%1 Year Performance-66.37%5.38%34.86%20.39% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.0124 of 5 stars$1.52+0.7%$12.00+689.5%-68.9%$107.22M$35.58M-1.03150RAPPRapport Therapeutics1.9166 of 5 stars$10.88-0.4%$32.67+200.2%N/A$398.55MN/A0.00N/ANews CoverageERASErasca3.0715 of 5 stars$1.39+1.5%$4.57+228.9%-44.3%$388.10MN/A0.00120Positive NewsBNTCBenitec Biopharma1.6325 of 5 stars$14.57-0.3%$23.83+63.6%+66.7%$383.52M$80K-9.6520High Trading VolumeITOSiTeos Therapeutics3.2341 of 5 stars$10.11+1.5%$15.86+56.8%-33.4%$381.21M$35M-3.3390RVNCRevance Therapeutics2.7157 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500ABVXAbivax2.4554 of 5 stars$6.11+2.3%$31.00+407.4%-43.5%$378.82MN/A0.0061Positive NewsFULCFulcrum Therapeutics0.3287 of 5 stars$7.17+2.6%$6.29-12.3%+8.4%$377.58M$80M-102.41100SLDBSolid Biosciences3.4191 of 5 stars$4.51-5.8%$14.90+230.4%-26.6%$371.30M$8.09M-1.51100CKPTCheckpoint Therapeutics0.5593 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210News CoverageTECXTectonic Therapeutic3.4747 of 5 stars$18.75-5.4%$82.33+339.1%+26.8%$369.90MN/A0.00120 Related Companies and Tools Related Companies Rapport Therapeutics Competitors Erasca Competitors Benitec Biopharma Competitors iTeos Therapeutics Competitors Revance Therapeutics Competitors Abivax Competitors Fulcrum Therapeutics Competitors Solid Biosciences Competitors Checkpoint Therapeutics Competitors Tectonic Therapeutic Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CCCC Stock Alerts